Ubix Therapeutics to Speak at ACCESS CHINA Partnering Forum

December 23rd, 2024 (Shanghai) — We are glad to announce that Hyunjin Yang, the Director of Business Development of Ubix Therapeutics, will be presenting at the ACCESS CHINA Partnering Forum @ JPM on January 7th-9th, and 21st-23rd, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.

About Ubix Therapeutics

Ubix Therapeutics is a clinical-stage biotech company dedicated to the development of heterobifunctional degrader drugs, also known as Targeted Protein Degradation (TPD), with a primary focus on oncology. The company’s wholly owned R&D programs include a BTK degrader in a Phase 1 clinical trial for the treatment of B cell malignancies and an SHP2 degrader in the lead optimization stage for the treatment of MAPK signaling-dependent tumors. Partnered programs include an AR degrader in the IND-enabling stage for the treatment of prostate cancer (out-licensed to Yuhan, a leading South Korean pharma company and the developer of J&J’s lazertinib, a 3rd generation EGFR TKI) and an immuno-oncology degrader (out-licensed to NeoImmuneTech). They are currently exploring the development of degrader-antibody conjugates (DAC).

About the speaker

Hyunjin Yang is a highly accomplished professional with a Ph.D. in Neurodevelopment from the University of Minnesota, USA, and postdoctoral training at the National Institutes of Health (NIH), where she specialized in transcriptional and epigenomic regulation during neurodevelopment and neurodegeneration.

After a decade of extensive research experience, she transitioned into the biotech industry, serving as Director of Business Development at Syntekabio, a genomics and AI-driven drug discovery company. There, she successfully sourced and managed partnerships with pharmaceutical companies and led technology evaluations for the company’s IPO. Currently, at Ubix Therapeutics, Hyunjin continues to lead business development efforts, recently closing significant out-licensing deals with Yuhan.

About ACCESS CHINA Partnering Forum

ACCESS CHINA Partnering Forum @ JPM is scheduled to be held on January 7th-9th, and 21st-23rd, 2025, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, the audience can have access to innovative pharma and healthcare products from worldwide.

Conference Name: ACCESS CHINA Partnering Forum

Date & Time: January 7-9 (Live), and 21-23(VoD), 2025, China time

Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception

Scale: Expected 500+ participants Online; 100 company roadshows

Participants: Pharma/Biotech senior management and BDs

View more information at https://biotochina.org/